Influence of radiation on the blood-brain barrier and optimum time of chemotherapy

Qin, Dashan; Zheng, Rong; Jin, Tao; Li, Jiaxiu; Hu, Yuhua

doi:10.1016/0360-3016(90)90364-p

Cited by 82 publications

(55 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Для уменьшения долгосроч-ной токсичности предпочтительнее фракциониро-вание с разовой ежедневной дозой 2 Гр [27]. В дру-гом исследовании [12] показано, что фракционная доза 2 Гр для изменения проницаемости ГЭБ может оптимизировать эффект химиотерапии. D. Qin и со-авт.…”

Section: Discussionunclassified

“…D. Qin и со-авт. заметили, что проницаемость ГЭБ внутри и во-круг опухоли только на 20% больше, чем в нормаль-ной ткани мозга [12]. Однако, несмотря на исследо-вания в этой области, радиотерапия в целях увели-чения проницаемости ГЭБ и эффективности химио-терапии до сих пор применяется ограниченно [7,28].…”

Section: Discussionunclassified

“…За последнее десятилетие сведения о молеку-лярных изменениях церебрального эндотелия, реак-ции астроглии, длительности и сроках открытия ге-матоэнцефалического барьера при фракциониро-ванном облучении представляют собой разрознен-ную информацию [10][11][12][13][14][15]. По-прежнему спорным и открытым вопросом в современной нейроонколо-гии остается проблема состояния когнитивной сфе-ры и качества жизни пациентов после цикла химио-или радиотерапии на фоне увеличения продолжи-тельности жизни [16,17].…”

unclassified

See 2 more Smart Citations

Blood—brain barrier permeability in healthy rats and rats with experimental C6 glioma after fractionated radiotherapy of the brain

et al. 2015

View full text Add to dashboard Cite

Section: Discussionunclassified

unclassified

See 1 more Smart Citation

Blood—brain barrier permeability in healthy rats and rats with experimental C6 glioma after fractionated radiotherapy of the brain

et al. 2015

View full text Add to dashboard Cite

“…Chemotherapeutic agents do not easily cross the blood-brain barrier, while radiation therapy is known to compromise the barrier function [15] by reducing the expression of the efflux transporter P-glycoprotein [16]. Evidence suggests that this effect may last for as long as several years after postradiation therapy [15].…”

Section: Discussionmentioning

confidence: 99%

Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?

Catania¹,

Malaguti²,

Gasparro³

et al. 2018

Oncology

View full text Add to dashboard Cite

Background: Brain metastases develop in approximately 10–25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis. Case Report: We report the case of a 40-year-old woman with MBC and associated lung, bone, liver, and brain metastases, who experienced a time to progression of several months with eribulin after whole-brain radiotherapy (WBRT), 2 lines of chemotherapy, and 1 line of hormonal therapy, maintaining a good toxicity profile. Discussion: Eribulin, in association with local treatment such as WBRT, can be well tolerated and effective in achieving a long progression-free survival and a good control of brain metastases in patients with MBC who have received multiple lines of treatment. The vascular remodeling properties of eribulin, combined with brain radiotherapy, might facilitate the passage of eribulin across the blood brain barrier, improving brain response. Conclusion: Our anecdotal experience suggests that eribulin may have a potentially beneficial effect on brain metastases while maintaining a good systemic control of the disease in patients with MBC.

show abstract

“…In GBM, drugs may not necessarily need to actively "cross" the BBB as these tumors usually present with a disrupted BBB [32,33], which is even further aggravated by radiotherapy [34][35][36]. However, although GBM is characterized by a high local relapse rate, it resembles a (central nervous) systemic disease as multiple tumor cells are occultly disseminated throughout the brain at the time of diagnosis [37].…”

Section: Discussionmentioning

confidence: 99%

The HIV-Derived Protein Vpr52-96 Has Antiglioma Activity In Vitro and In Vivo

Giordano

Kübler

Kirschner

et al. 2015

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Patients with actively replicating human immunodeficiency virus (HIV) exhibitadverse reactions even to low irradiation doses. High levels of the virus-encoded viral protein R (Vpr) are believed to be one of the major underlying causes for increased radiosensitivity. As Vpr efficiently crosses the blood-brain barrier and accumulates in astrocytes, we examined its efficacy as a drug for treatment of glioblastoma multiforme (GBM).In vitro, four glioblastoma-derived cell lines with and without methylguanine-DNA methyltransferase (MGMT) overexpression (U251, U87, U251-MGMT, U87-MGMT) were exposed to Vpr, temozolomide (TMZ), conventional photon irradiation (2 to 6 Gy) or to combinations thereof. Vpr showed high rates of acute toxicities with median effective doses of 4.0±1.1 μM and 15.7±7.5 μM for U251 and U87 cells, respectively. Caspase assays revealed Vpr-induced apoptosis in U251, but not in U87 cells. Vpr also efficiently inhibited clonogenic survival in both U251 and U87 cells and acted additively with irradiation. In contrast to TMZ, Vpr acted independently of MGMT expression.Dose escalation in mice (n=12) was feasible and resulted in no evident renal or liver toxicity. Both, irradiation with 3x5 Gy (n=8) and treatment with Vpr (n=5) delayed intracerebral tumor growth and prolonged overall survival compared to untreated animals (n=5; p 3x5 Gy <0.001 and p Vpr =0.04; log-rank test).Our data show that the HIV-encoded peptide Vpr exhibits all properties of an effective chemotherapeutic drug and may be a useful agent in the treatment of GBM.

show abstract

Influence of radiation on the blood-brain barrier and optimum time of chemotherapy

Cited by 82 publications

References 6 publications

Blood—brain barrier permeability in healthy rats and rats with experimental C6 glioma after fractionated radiotherapy of the brain

Blood—brain barrier permeability in healthy rats and rats with experimental C6 glioma after fractionated radiotherapy of the brain

Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?

The HIV-Derived Protein Vpr52-96 Has Antiglioma Activity In Vitro and In Vivo

Contact Info

Product

Resources

About